DSIP
Also known as Delta Sleep-Inducing Peptide
An endogenous-like nonapeptide investigated for possible roles in sleep physiology, stress signaling, and neuroendocrine regulation.
- Regulatory status
- Investigational / research peptide
DSIP is not an approved treatment for insomnia or any other condition in the United States or elsewhere.
- Half-life
- Human pharmacokinetic half-life not well established.
Animal pharmacokinetic values are sometimes quoted online; they are not a substitute for human data and are not reproduced here as human half-life.
- Route
- Intravenous and subcutaneous in published experimental studies
Research use / investigational only. No validated clinical route of administration.
- Evidence
- Multiple randomized controlled trials in humans
Mechanism of action
The primary receptor and exact molecular mechanism of DSIP remain incompletely characterized. Research has examined possible modulation of sleep-wake physiology, neuroendocrine signaling, stress responses, circadian physiology, thermoregulation, and pain-related signaling, largely in animal and older human experimental work. No specific receptor target has been reliably established.
Studied and reported uses
Sleep physiology
Historically studied for possible effects on sleep onset and sleep architecture. Human data are older, small, and mixed.
Stress physiology
Experimental literature has examined potential effects on physiological stress responses, mostly in animal models.
Circadian regulation
Some reported effects appear influenced by circadian state and timing of administration.
Neuroendocrine research
Investigated for possible interactions between central nervous system signaling and endocrine output.
Dosing information
Ranges are reported from literature and clinical labeling for reference only. They are not a dosing recommendation.
Published research has used different experimental protocols depending on the compound, formulation, route, indication and study design. These study protocols should not be interpreted as established clinical dosing recommendations.
Important pharmacology
Mechanistic uncertainty
Because no validated receptor has been identified, pharmacodynamic predictions for DSIP are speculative. Mechanistic and animal findings should not be read as demonstrated human effects.
Context dependence
Reported effects in the literature vary with timing, species, and experimental model, which complicates translation to human sleep outcomes.
Side effects
- Human safety data limited
- Tolerability not well characterized
Human safety and long-term tolerability are not well characterized. Published studies are small and old, and a reliable adverse-event profile cannot be stated from the available evidence.
Research evidence
Early human sleep studies
Human Clinical Trial (older, small): reported effects on sleep parameters were inconsistent across studies.
Animal sleep and stress models
Animal: preclinical studies suggest modulation of sleep-related and stress-related physiology.
Neuroendocrine investigations
Mechanistic: studies have examined interactions with pituitary and stress-hormone signaling.
Overall evidence position
Review: modern controlled human clinical evidence remains limited and mixed.
Scientific references
Delta sleep-inducing peptide (DSIP): a still unresolved riddle
Kovalzon VM, Strekalova TV · Journal of Neurochemistry · 2006
Journal of Neurochemistry (PubMed-indexed review)
ReviewPubMedIsolation of a sleep-inducing peptide from cerebral venous blood
Schoenenberger GA, Monnier M · PNAS · 1977
Original isolation work by Monnier and Schoenenberger
AnimalPubMedDSIP in human sleep: clinical observations
Neuropsychobiology · 1984
Older human experimental sleep literature (PubMed-indexed)
Human Clinical TrialPubMedDSIP and neuroendocrine regulation
PubMed-indexed mechanistic studies
MechanisticPubMedDSIP effects on stress responses in animal models
PubMed-indexed preclinical studies
AnimalPubMed